Pre-made Guselkumab benchmark antibody ( Whole mAb, anti-IL23A/IL23 therapeutic antibody, Anti-IL23P19/P19/SGRF Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-255

Pre-Made Guselkumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-255-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Guselkumab biosimilar, Whole mAb, Anti-IL23A/IL23 Antibody: Anti-IL23P19/P19/SGRF therapeutic antibody
INN Name Guselkumab
TargetIL23
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure4m6m:HL/4m6n:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesJanssen Biotech;MorphoSys;Taiho Pharmaceutical
Conditions ApprovedErythrodermic psoriasis;Palmoplantar pustulosis;Plaque psoriasis;Psoriatic arthritis;Pustular psoriasis
Conditions ActiveCrohn's disease;Hidradenitis suppurativa;Ulcerative colitis;Familial adenomatous polyposis;Psoriasis;Giant cell arteritis;Lupus nephritis;Systemic scleroderma
Conditions DiscontinuedRheumatoid arthritis
Development TechMorphoSys HuCAL Phage Display